**Poisoning due to ingestion of amatoxin-containing mushrooms in South Korea: A systematic review and meta-analysis**

Chiwon Ahn,1 Hyunggoo Kang,2,\* Tae Ho Lim,2 and Jaehoon Oh2

1Department of Emergency Medicine, College of Medicine, Chung-Ang University, Seoul, 06974, Korea

2Department of Emergency Medicine, College of Medicine, Hanyang University, Seoul, 04763, Korea

**E-mail address for authors:**

Chiwon Ahn: dr.ahn@hanmail.net

Hyunggoo Kang: emer0905@gmail.com

Tae Ho Lim: erthim@gmail.com

Jaehoon Oh: ojjai@hanmail.net

\***Address for correspondence:**

Hyunggoo Kang, MD, PhD

Department of Emergency Medicine, Hanyang University College of Medicine,

222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea

Tel: +82-2-2290-8999

Fax: +82-2-2290-9280

E-mail: emer0905@gmail.com

**Supplemental Table 1. Search strategy**

|  |  |
| --- | --- |
| Database | Search term |
| EMBASE | ((“mushroom” OR “toadstool[mp]” OR “Amanita” OR “Amanita phalloides”) AND (“intoxication” OR “toxicity” OR “acute toxicity” OR “poisoning[mp]”)) OR (“mushroom poisoning” OR “poisonous mushroom” OR) |
| MEDLINE | (“mushroom[mp]” OR “toadstool[mp]” OR “Amanita”[MeSH]) AND (“intoxication[mp]” OR “toxicity[mp]” OR “Poisoning”[MeSH])) OR (“Mushroom Poisoning”[MeSH]) |
| Web of Science | (TS=(mushroom OR toadstool OR amanita) AND TS=(intoxication OR toxicity OR poisoning)) OR (TS=mushroom poisoning) |
| KMbase | “mushroom” OR “amanita” OR “amatoxin” |
| KISS | (“mushroom” OR “amanita” OR “amatoxin”) and (“poisoning” OR “intoxication”) |

**Supplementary Table 2. The quality assessment checklist of 18-item validated quality appraisal tool for case series.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Lee 1990 | Yoo 1998 | Jung 1999 | Rho 2000 | Oh 2004 |
| Study objective |  |  |  |  |  |
| 1. Is the hypothesis/aim/objective of the study clearly stated in the abstract, introduction, or methods section? | O | O | O | O | O |
| Study population |  |  |  |  |  |
| 2. Are the characteristics of the participants included in the study described? | O | O | O | O | O |
| 3. Were the cases collected in more than one centre? | - | - | - | - | - |
| 4. Are the eligibility criteria (inclusion and exclusion criteria) to entry the study explicit and appropriate? | O | O | O | O | O |
| 5. Were participants recruited consecutively? | O | O | - | O | O |
| 6. Did participants enter the study at a similar point in the disease? | - | - | O | - | O |
| Intervention and co-intervention |  |  |  |  |  |
| 7. Was the intervention clearly described in the study? | - | O | O | O | - |
| 8. Were additional interventions (co-interventions) clearly reported in the study? | O | O | O | O | - |
| Outcome measures |  |  |  |  |  |
| 9. Are the outcome measures clearly defined in the introduction or methods section? | O | O | - | O | O |
| 10. Were relevant outcomes appropriately measured with objective and/or subjective methods? | O | O | - | O | O |
| 11. Were outcomes measured before and after intervention? | O | O | - | O | O |
| Statistical analysis |  |  |  |  |  |
| 12. Were the statistical tests used to assess the relevant outcomes appropriate? | O | - | - | - | O |
| Results and conclusions |  |  |  |  |  |
| 13. Was the length of follow-up reported? | - | O | - | O | O |
| 14. Was the loss to follow-up reported? | - | O | - | O | O |
| 15. Does the study provide estimates of the random variability in the data analysis of relevant outcomes? | O | - | - | - | O |
| 16. Are adverse events reported? | - | O | - | O | O |
| 17. Are the conclusions of the study supported by results? | O | O | O | O | O |
| Competing interest and source of support |  |  |  |  |  |
| 18. Are both competing interest and source of support for the study reported? | - | - | - | - | - |
|  | 11/18 | 13/18 | 7/18 | 13/18 | 14/18 |